(3R)-1-[(3,4-difluorophenyl)methyl]-3-methylpiperazine | 945027-67-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3R)-1-[(3,4-difluorophenyl)methyl]-3-methylpiperazine
• CAS: 945027-67-8
• 化学式: C₁₂H₁₆F₂N₂
• 分子量: 226.269
• InChiKey: OAAJLEBVUQMPQH-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3R)-1-[(3,4-difluorophenyl)methyl]-3-methylpiperazine 在 potassium carbonate 、 N,N-二异丙基乙胺 、 potassium iodide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-3-(2-(2-(4-(3,4-difluorobenzyl)-2-methylpiperazin-1-yl)-2-oxoethoxy)-5-chlorophenylamino)-4-(methylamino)cyclobut-3-ene-1,2-dione
  参考文献：
  名称：

  Structure–activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists

  摘要：

  Design and synthesis of a series of 3-amino-4-(2-(2-(4-benzylpiperazin-1-yl)-2-oxoethoxy)phenylamino)cyclobutenedione derivatives as novel CCRI antagonists are described. Structure-activity relationship studies led to the identification of compound 22, which demonstrated potent binding activity, functional antagonism of CCR1 as well as good species cross-reactivity. In addition, compound 22 also showed desirable pharmacokinetic profiles and was selected for in vivo studies in the mouse collagen-induced arthritis model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.104
• 作为产物：
  描述：

  (R)-(-)-2-甲基哌嗪 、 3,4-二氟氯苄 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (3R)-1-[(3,4-difluorophenyl)methyl]-3-methylpiperazine
  参考文献：
  名称：

  Structure–activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists

  摘要：

  Design and synthesis of a series of 3-amino-4-(2-(2-(4-benzylpiperazin-1-yl)-2-oxoethoxy)phenylamino)cyclobutenedione derivatives as novel CCRI antagonists are described. Structure-activity relationship studies led to the identification of compound 22, which demonstrated potent binding activity, functional antagonism of CCR1 as well as good species cross-reactivity. In addition, compound 22 also showed desirable pharmacokinetic profiles and was selected for in vivo studies in the mouse collagen-induced arthritis model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.104